Reneo Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 51.96 million compared to USD 39.77 million a year ago. Basic loss per share from continuing operations was USD 2.12 compared to USD 2.19 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | +4.82% | -7.94% | +8.75% |
05-16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
05-13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.75% | 58.15M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.40% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- RPHM Stock
- News Reneo Pharmaceuticals, Inc.
- Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022